Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.

Bourgeois, Wallace; Cutler, Jevon A; Aubrey, Brandon J; Wenge, Daniela V; Perner, Florian; Martucci, Cynthia; Henrich, Jill A; Klega, Kelly; Nowak, Radoslaw P; Donovan, Katherine A; Boileau, Meaghan; Wen, Yanhe; Hatton, Charlie; Apazidis, Athina A; Olsen, Sarah Naomi; Kirmani, Nadia; Pikman, Yana; Pollard, Jessica A; Perry, Jennifer A; Sperling, Adam S; Ebert, Benjamin L; McGeehan, Gerard M; Crompton, Brian D; Fischer, Eric S; Armstrong, Scott A

Bourgeois, Wallace; Cutler, Jevon A; Aubrey, Brandon J; Wenge, Daniela V; Perner, Florian; Martucci, Cynthia; Henrich, Jill A; Klega, Kelly; Nowak, Radoslaw P; Donovan, Katherine A; Boileau, Meaghan; Wen, Yanhe; Hatton, Charlie; Apazidis, Athina A; Olsen, Sarah Naomi; Kirmani, Nadia; Pikman, Yana; Pollard, Jessica A; Perry, Jennifer A; Sperling, Adam S; Ebert, Benjamin L; McGeehan, Gerard M; Crompton, Brian D; Fischer, Eric S; Armstrong, Scott A.

Affiliation

Bourgeois W; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Cutler JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Aubrey BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Wenge DV; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Perner F; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Martucci C; Internal Medicine C, University Medicine Greifswald, Greifswald, Germany.
Henrich JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Klega K; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Nowak RP; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Boileau M; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA.
Wen Y; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Hatton C; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA.
Apazidis AA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Olsen SN; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Kirmani N; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Pikman Y; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Pollard JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Perry JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Sperling AS; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Ebert BL; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
McGeehan GM; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Crompton BD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Fischer ES; Division of Hematology, Brigham and Women's Hospital, Boston, MA.
Armstrong SA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Blood ; 143(15): 1513-1527, 2024 Apr 11.

Article de En | MEDLINE | ID: mdl-38096371

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Phtalimides / Pipéridones / Leucémie aigüe myéloïde / Morpholines / Protéine de la leucémie myéloïde-lymphoïde Limites: Humans Langue: En Journal: Blood Année: 2024 Type de document: Article Pays d'affiliation: Maroc Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google